Holen Sie sich die Stockscreener-App
185.62
0.01%
-0.00
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$185.62
Offen:
$185.01
24-Stunden-Volumen:
324.35K
Relative Volume:
0.04
Marktkapitalisierung:
$334.73B
Einnahmen:
$57.37B
Nettoeinkommen (Verlust:
$4.20B
KGV:
78.99
EPS:
2.35
Netto-Cashflow:
$15.39B
1W Leistung:
+0.03%
1M Leistung:
-0.27%
6M Leistung:
+4.45%
1J Leistung:
+8.94%
1-Tages-Spanne:
$184.38
$185.53
1-Wochen-Bereich:
$181.73
$188.99
52-Wochen-Spanne:
$163.52
$218.66
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Vergleichen Sie ABBV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
185.50 | 334.73B | 57.37B | 4.20B | 15.39B | 2.35 |
|
LLY
Lilly Eli Co
|
780.87 | 724.64B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
153.61 | 376.43B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVO
Novo Nordisk Adr
|
68.43 | 352.49B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
NVS
Novartis Ag Adr
|
122.47 | 234.21B | 53.22B | 12.86B | 14.85B | 6.39 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
AbbVie (NYSE:ABBV) migraine drug update boosts biotech pipeline strength S&P 500 - Kalkine Media
AbbVie (NYSE:ABBV) Announces Positive Phase 3 Results for Migraine Drug Atogepant - Yahoo Finance
AbbVie's migraine drug meets main goal in head-to-head study with topiramate - Reuters
AbbVie's Migraine Drug Achieves Superiority In Preventing Headaches Compared To Generic Treatment In Head To Head Trial - Benzinga
AbbVie’s atogepant achieves superiority in migraine prevention - The Pharma Letter
AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention - PharmaLive
AbbVie (ABBV) Sees Success with Migraine Drug Atogepant in Late-Stage Trial - GuruFocus
AbbVie Stock (ABBV) Dips: A Buying Opportunity for its 3.55% Dividend Yield? - Daily Chhattisgarh News
Hidradenitis Suppurativa Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | InflaRx, Novartis, UCB, AbbVie, Pfizer, Amgen, Incyte, CSL Behring - Barchart.com
AbbVie succeeds in late-stage migraine treatment trial (ABBV) - Seeking Alpha
AbbVie’s migraine drug meets main goal of late-stage study - 1470 & 100.3 WMBD
AbbVie (ABBV) Reports Positive Results from Migraine Study | ABBV Stock News - GuruFocus
AbbVie Reports Positive Topline Results From Phase 3 TEMPLE Study Of Atogepant For Migrane - Nasdaq
AbbVie Announces New Data Demonstrating Atogepant Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention - Investing News Network
Fibrotic Diseases Treatment Market Top Companies StudyAbbVie - openPR.com
AbbVie’s atogepant shows superior results in migraine prevention trial By Investing.com - Investing.com Canada
AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention | ABBV St - GuruFocus
AbbVie's migraine drug meets main goal of late-stage study - TradingView
Here's Why AbbVie (ABBV) Fell More Than Broader Market - Yahoo Finance
AbbVie’s $1.6 Billion Break Fee Sidesteps Capital Loss Limit (1) - news.bloombergtax.com
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes - Investing News Network
AbbVie (ABBV) Faces Potential Challenges Amid U.S. Advertising P - GuruFocus
RFK Jr. plans crackdown on pharma ads in threat to AbbVie's $2 billion marketing strategy - Crain's Chicago Business
AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes - Benzinga
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study - Nasdaq
Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic? - Nasdaq
AbbVie says Phase 3 Verona trial of venetoclax/azacitidine did not meet endpoint - Yahoo Finance
AbbVie's Diversification Strategy Cushions Venetoclax MDS Blow (NYSE:ABBV) - Seeking Alpha
AbbVie, ADARx Pharmaceuticals Partner to Develop Next-Gen siRNA Therapeutics - MSN
AbbVie (ABBV) Pipeline Bolstered as FDA Approves Mavyret Label Expansion for Hepatitis C - Insider Monkey
AbbVie says blood cancer drug fails late-stage trial - Reuters
Sector Update: Health Care Stocks Retreat Late Afternoon - MarketScreener
Sector Update: Health Care - marketscreener.com
AbbVie cancer drug misses the mark in trial for new use - Crain's Chicago Business
AbbVie (ABBV) and Genentech Report Phase III Study Results for Venclexta | ABBV Stock News - GuruFocus
AbbVie (ABBV) Faces Setback in VERONA Study for Venclexta | ABBV Stock News - GuruFocus
AbbVie stock dips after cancer drug trial setback - TradingView
AbbVie (ABBV) Faces Setback with Leukemia Drug Trial - GuruFocus
AbbVie fails in late-stage trial for Roche-partnered blood cancer therapy venetoclax - Seeking Alpha
AbbVie: trial fails in myelodysplastic syndrome - MarketScreener
AbbVie's Venetoclax Doesn't Meet Primary Endpoint in Trial for Higher-Risk Myelodysplastic Syndrome Treatment - MarketScreener
Here's Why AbbVie (ABBV) is a Strong Value Stock - Yahoo Finance
AbbVie Says Myelodysplastic Syndrome Phase 3 Trial Failed to Meet Primary Endpoint - marketscreener.com
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Highe - GuruFocus
AbbVie (ABBV) Phase 3 Trial on Myelodysplastic Syndrome Falls Short | ABBV Stock News - GuruFocus
AbbVie’s venetoclax fails in phase 3 trial for MDS treatment By Investing.com - Investing.com Canada
5 Large Drug Stocks That Are Poised to Ride on Sector Recovery - Yahoo Finance
AbbVie Provides Update On VERONA Trial For Newly Diagnosed Higher-Risk Myelodysplastic Syndromes - marketscreener.com
AbbVie's Phase 3 VERONA Trial Falls Short: Key Results for Venetoclax MDS Treatment Revealed - Stock Titan
AbbVie: Margin Clarity, Dividend Durability Awaited (NYSE:ABBV) - Seeking Alpha
AbbVie, Chicago Cubs step up to plate to hit a cancer research grand slam - Medical Marketing and Media
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
Abbvie Inc-Aktie (ABBV) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER |
Mar 31 '25 |
Sale |
210.08 |
58,832 |
12,359,504 |
53,234 |
0.92%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):